AstraZeneca adds new heart failure target through collaboration with BenevolentAI
Betsy Goodfellow | May 15, 2024 | News story | Research and Development | AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ ongoing collaboration.
The collaboration began in 2019, with its original focus being the discovery of potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD), later being expanded in 2022 to two new disease areas ‒ heart failure and systemic lupus erythematosus (SLE).
Throughout the collaboration, scientists and technologists from the two companies have worked together using BenevolentAI’s artificial intelligence (AI)-driven drug discovery platform and biomedical knowledge, along with AstraZeneca’s scientific and disease-specific expertise.
The initial and extended collaboration were agreed on similar terms, including upfront payments on signing, research funding and discovery, development and commercial milestones.
Dr Anne Phelan, chief scientific officer at BenevolentAI, commented: “I am delighted that AstraZeneca has selected one of the novel heart failure targets that we have been jointly working on to enter its portfolio. heart failure is a therapeutic area where there is significant medical need but, due to the size of the market, requires a team effort and significant momentum, so we are delighted to be working with AstraZeneca in this important field of medicine.”
Betsy Goodfellow
Related Content
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …
Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies
Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license …